Recross Cardio Inc
Reducing the Risk of Stroke Through PFO Closure. Recross Cardio is a medical device company resolving patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients with PFO-associated stroke. We have initiated the U.S. FDA approved Early Feasibility Study (EFS), The PROTEA-PFO Study, to demonstrate the safety and efficacy of our P3 Occluder System.
7-day free trial · no credit card
Verified contacts
4
available on Kipplo
LinkedIn employees
8
1 to 10 range
Open roles
—
no listings
Distinct roles
4
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 4 verified contacts at Recross Cardio Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
4 contacts with verified email or phone · masked until revealed.
- CP
Cecilia Petrella
Director Clinical Affairs · Healthcare & Human Services
EmailPhone - TG
Thomas Gerhardt
Chief Executive Officer · Other
EmailPhone
Showing 2 of 4 verified contacts
Top roles at Recross Cardio Inc
4 distinct titles indexed · top 4 shown.
- 1chief executive officer
- 1co-founder & clinical advisor
- 1director clinical affairs
- 1r & d manager
Sign up to unlock all 4 contacts at Recross Cardio Inc
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 4 verified contacts at Recross Cardio Inc
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.